Gene symbol | STAT3 | Synonyms | ADMIO, ADMIO1, APRF, HIES | Type of gene | protein-coding |
Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
Description | signal transducer and activator of transcription 3 |
GTO ID | GTC3404 |
Trial ID | NCT05814666 |
Disease | Head and Neck Squamous Cell Carcinoma |
Altered gene | STAT3 |
Therapeutic/Target gene | Target gene |
Therapy | ASO |
Treatment | ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx |
Co-treatment | pembrolizumab |
Phase | Phase2 |
Recruitment status | Recruiting |
Title | An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
Year | 2023 |
Country | United States|Korea, Republic of |
Company sponsor | Flamingo Therapeutics NV |
Other ID(s) | FLM-6774-201 |
Vector information | |||
|
Cohort1: Danvatirsen_pembrolizumab | |||||||
|
|||||||
Cohort2: pembrolizumab | |||||||
|